




REALIZE EFFECTIVE PHARMACEUTICALS

The Measure of Confidence



Agilent Technologies



HOW DO YOU SUCCEED




WHEN THE ODDS AGAINST YOU ARE INCREASING?

The pharmaceutical industry faces constant challenges, as business, science, and regulatory pressures evolve and collide. From personalized medicine, to CROs, to the rise of biologics, the process of bringing drugs to market today is dramatically different than it was ten years ago. What will it look like ten years from now?

The solution lies in finding effective ways to minimize risks and identify winners early on. At Agilent Technologies, we have developed a comprehensive portfolio of measurement platforms to help you achieve exactly that. From the most critical assessments to the routine analyses, we believe that companies need more than just good data—they need answers that help them make faster, smarter decisions about how to proceed.

RATHER THAN BE DAUNTED BY THESE CHALLENGES, AT AGILENT, WE HAVE A DIFFERENT IDEA: WHAT IF WE SIMPLY GET BETTER AT REVEALING THE PATH TO SUCCESS?





YOU TURN **COMPLEXITY**




Agilent offers innovative disease research solutions to maximize insights gathered from every result, including the 6550 iFunnel Q-TOF LC/MS System, GeneSpring Bioinformatics Software, and the SureSelect Target Enrichment Platform.

TO YOUR ADVANTAGE

Knowledge of disease mechanisms is exploding, and the omics revolution has only just begun. The more we learn, the more we uncover the daunting complexity of biological systems. Yet, contained within this tangled maze are the answers needed to create new and better pharmaceuticals.

At Agilent, we believe that extracting meaningful knowledge from complexity begins with better measurement. With platforms that enable targeted resequencing, we're powering the effort to match patient subpopulations with the right drug candidates. With products designed in conjunction with the metabolomics and proteomics communities, we are making biomarker identification faster, easier, and more robust. Our focus on integrating multi-omic approaches is helping identify promising drug targets for complex diseases.

EVERYTHING WE DO TO SUPPORT DISEASE RESEARCH IS DESIGNED TO PROVIDE NOT JUST ANSWERS, BUT THE CONTEXT FOR THEM, BRINGING INSIGHT THAT TRANSFORMS SIMPLE MEASUREMENT INTO A ROADMAP FOR THE PATH AHEAD.




YOU MAKE SMARTER,

Identifying one successful candidate among millions of others means repeatedly asking one deceptively simple question—keep or throw away? Each time that decision is made you must weigh opportunity against risk using the most reliable data possible, because at every step branching out before you are the paths to both failure and success.

Agilent's long standing expertise in measurement is driving the development of tomorrow's streamlined engines of discovery. We help companies quickly analyze samples, at the scale they need, from screening to kinetics to structural analysis. With innovations in purification and separation techniques, we are helping companies characterize new drug candidates with greater speed and efficiency.

OUR PLATFORMS ARE OPTIMIZED TO PROVIDE THE DATA YOU NEED TO PROPEL DRUG DISCOVERY FORWARD, SO YOU HAVE FULL CONFIDENCE EVERY TIME YOU ASK THE QUESTION—KEEP OR THROW AWAY?



BETTER INFORMED CHOICES



Agilent's drug discovery portfolio maximizes the information you need for smarter decision-making. These include the RapidFire High-throughput MS platform, the 400 MHz NMR system, and the AssayMAP Bravo Platform for protein sample preparation.




It's not just about knowing what you have, it's about knowing how to use it. You need to constantly refine and optimize to achieve the perfect marriage of efficacy and safety, every single time.

At Agilent, we know that confidence in your answers grows from confidence in the tools themselves—confidence that they'll be easy to use and maintain, and confident they will deliver reproducible results with maximum efficiency. Our LC and MS systems are built to provide easy access to leading-edge method development, while our OpenLAB software suite has proven significant in helping companies normalize results across organizations and different instrumentation brands.

WHEN IT COMES TO DRUG DEVELOPMENT, WE BELIEVE THAT THE LATEST ADVANCES IN TECHNOLOGY MUST BE COMBINED WITH RUGGED RELIABILITY TO ENSURE THAT YOU ALWAYS HAVE THE BEST INFORMATION TO GUIDE YOUR PATH.

PROCESS UNTIL IT RUNS EFFICIENTLY



Agilent's portfolio of solutions for drug development enable the most rapid and robust methods through systems like our 1290 Infinity Series LC Platform (UHPLC), 6490 Triple Quadrupole Mass Spectrometer, and our wide range of LC Columns.

AND **YOU** TURN TO THE



PARTNER WHO HAS BEEN THERE ALL ALONG

Agilent has a decades-long history of supplying rock-solid analytical platforms for all aspects of pharmaceutical development. Ranked #1 in compliance since 1995, we have deep expertise in quality testing across the full spectrum of analytical techniques. Our innovations in software and service make system qualification as routine as the analysis itself.

WITH THE RIGHT PARTNER YOU REALIZE GREATER SUCCESS. WITH AGILENT'S COMMITMENT TO MEASUREMENT, YOU ACHIEVE IT EVERY STEP OF THE WAY.



Agilent's innovative technologies increase access to routine, robust measurement for drug manufacturing and QC; solutions include the 709-DS Dissolution Apparatus, the 720/730 Series ICP-OES Spectrometers, and the 6100 Series Single Quadrupole LC/MS Systems.



Learn more

www.agilent.com

Find a local Agilent customer center

www.agilent.com/chem/contactus

U.S. and Canada

1-800-227-9770

agilent_inquiries@agilent.com

Europe

info_agilent@agilent.com

Asia Pacific

inquiry_lsca@agilent.com

For Research Use Only. Not for use in diagnostic procedures.
This information is subject to change without notice.

© Agilent Technologies, Inc. 2012
Printed in the USA May 30, 2012
5991-0537EN



Agilent Technologies